Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2014-05-05 (11 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BOURGES (18000), Cher
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DE TURLY : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE TURLY is a French company
founded 11 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BOURGES (18000),
this company of category PME
shows in 2025 a net income positive of 161 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE TURLY (SIREN 802133397)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
160 541 €
144 281 €
167 151 €
315 891 €
248 372 €
190 836 €
169 542 €
120 468 €
140 167 €
129 045 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DE TURLY generates positive net income of 161 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 129 k€ -> 161 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
160 541 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 71%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
28.884%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
70.66%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE TURLY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
252.629
175.208
125.596
213.151
150.811
110.106
73.402
55.806
41.262
28.884
Financial autonomy
25.486
33.066
41.103
28.728
35.619
41.857
51.079
58.955
64.836
70.66
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
28.882025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good-9 pts over 3 years
In 2025, the debt ratio of SELARL PHARMACIE DE TURLY (28.88) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
70.66%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good+10 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE DE TURLY (70.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 230.76. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
230.76
Liquidity indicators evolution SELARL PHARMACIE DE TURLY
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
206.674
241.09
278.899
216.843
212.376
216.357
244.227
289.111
268.143
230.76
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
230.762025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good-9 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE DE TURLY (230.76) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of SELARL PHARMACIE DE TURLY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DE TURLY is estimated at
2 550 212 €
(range 1 730 586€ - 4 001 635€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1730k€2550k€4001k€
2 550 212 €Range: 1 730 586€ - 4 001 635€
NAF 5 année 2025
Valuation method used
Net Income Multiple
160 541 €
×
15.9x
=2 550 213 €
Range: 1 730 587€ - 4 001 635€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE TURLY with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE TURLY
What is the revenue of SELARL PHARMACIE DE TURLY ?
The revenue of SELARL PHARMACIE DE TURLY is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE DE TURLY profitable?
Yes, SELARL PHARMACIE DE TURLY generated a net profit of 161 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DE TURLY ?
The headquarters of SELARL PHARMACIE DE TURLY is located in BOURGES (18000), in the department Cher.
Where to find the tax return of SELARL PHARMACIE DE TURLY ?
The tax return of SELARL PHARMACIE DE TURLY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE TURLY operate?
SELARL PHARMACIE DE TURLY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart